Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hutchison China MediTech Says Fruquintinib Increased Median Survival 41%

publication date: Jun 2, 2017
Hutchison China MediTech (Chi-Med) reported positive survival data for its lead drug, fruquintinib. In a pivotal Phase III China trial, fruquintinib increased median survival in 416 colorectal cancer patients from 6.6 months to 9.3 months, a 41% improvement. Chi-Med released the data in conjunction with the current ASCO meeting in Chicago. In March, the company announced the trial was successful, but did not release details. Chi-Med, which partnered China development of fruquintinib with Lilly, plans to file an NDA with the CFDA for the drug. More details....

Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital